Pharmacodynamic assessments
melanoma
MELANOMA
In general, the median level of pERK staining in evaluable sample pairs from each of 5 melanoma Q2D expansion cohorts (Supplementary Table S3), was lower at day 21 than baseline as assessed by H-score by a pathologist (median percentage decrease ≥ 70% in the 